NASDAQ:SUPN
Supernus Pharmaceuticals Stock News
$28.05
-0.720 (-2.50%)
At Close: May 21, 2024
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
04:15pm, Wednesday, 27'th Sep 2023
ROCKVILLE, Md., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
09:56pm, Tuesday, 08'th Aug 2023
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare t
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
09:11pm, Tuesday, 08'th Aug 2023
Supernus Pharmaceuticals (SUPN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.23. This compares to earnings of $0.14 per share a year ago.
Radcliffe Capital Management, L.P. Acquires Stake in Portage Fintech Acquisition Corp
04:37pm, Thursday, 27'th Jul 2023
Radcliffe Capital Management, L.P. (Trades, Portfolio), a prominent investment firm, recently made a significant acquisition in the stock market.
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
04:05pm, Monday, 24'th Jul 2023
ROCKVILLE, Md., July 24, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus: Rebuilding In Progress, But At An Inadequate Pace
11:59am, Monday, 12'th Jun 2023
Supernus Pharmaceuticals faces declining revenues from its long-time top seller Trokendi XR due to generic competition. Despite Trokendi's struggles, Supernus reported a slim increase in aggregate qua
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
07:40am, Saturday, 10'th Jun 2023
Supernus Pharmaceuticals is facing generic competition for its drug Trokendi. It's also scaling up its revenue for its medicine Qelbree.
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
10:09pm, Tuesday, 09'th May 2023
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Earnings Call Transcript
09:43pm, Tuesday, 09'th May 2023
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Ca
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates
08:37pm, Tuesday, 09'th May 2023
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.43 per share a year ago.
Supernus to Present at the Bank of America 2023 Health Care Conference
04:05pm, Tuesday, 02'nd May 2023
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
04:15pm, Tuesday, 25'th Apr 2023
ROCKVILLE, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus to Participate in Two Upcoming Investor Conferences
04:05pm, Wednesday, 08'th Mar 2023
ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus to Present at the Cowen 43rd Annual Health Care Conference
04:55pm, Wednesday, 01'st Mar 2023
ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2022 Earnings Call Transcript
09:33pm, Tuesday, 28'th Feb 2023
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Confer
